US equities |
SPCX $167.08 ▲+5.11% NVDA $236.91 ▲+1.27% MU $1,063.88 ▼-1.02% TSLA $378.18 ▲+2.05% MSFT $526.44 ▲+1.72% SNDK $1,716.19 ▼-0.22% INTC $116.70 ▼-2.20% META $746.13 ▲+2.48%
FinancialContent

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

24.75 -0.41 (-1.61%)
Delayed Quote Updated: 11:25 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday ↗
 
Via Benzinga
News headline image
Assessing Arcutis Biotherapeutics: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Arcutis Biotherapeutics Through Analyst Insights ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
4 Analysts Have This To Say About Arcutis Biotherapeutics ↗
 
Via Benzinga
News headline image
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025. 
Via Investor's Business Daily
News headline image
Demystifying Arcutis Biotherapeutics: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 ↗
 
Via Benzinga
News headline image
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
CAVA Group Posts Strong Q2 Results, Joins Bilibili, Workday And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Titan Machinery Reports Weak Preliminary Results, Joins Precigen, Gogoro And Other Big Stocks Moving Lower In Thursday Pre-Market Session ↗
 
Via Benzinga
News headline image
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
ARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
ARQT stock results show that Arcutis Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks to Keep on Your Clinical Radar ↗
Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >